CELLULAR GOODS PLC — Major Shareholding Notification 2021

Oct 4, 2021

National Storage Mechanism | Additional information

RNS Number : 8244N

Cellular Goods PLC

04 October 2021

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Press release

4 October 2021

Cellular Goods PLC

("Cellular Goods" or "the Company")

Director dealings & TR1 notification

Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products formulated with lab-made cannabinoids, announces that Alexis Abraham, chief executive, purchased two million ordinary shares in the Company at 7.75 pence each on 1 October 2021.

The acquisition has increased his total holding to 20.5 million shares, representing 4.1% of the issued capital in the Company, as per the notification below.

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:			Cellular Goods plc LEI: 213800IXPX4Z2MKX2U28
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name			Alexis Abraham, CEO
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:			1 Oct. 2021
6. Date on which issuer notified (DD/MM/YYYY):			1 Oct. 2021
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached	4.1%	n/a			504,750,000
Position of previous notification (if applicable)	3.7%	n/a		3.7%	504,750,000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rightsix					% of voting rights
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BK964W87		20,500,000		n/a			4.1%		n/a
SUBTOTAL 8. A		20,500,000					4.1%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration datex	Exercise/ Conversion Periodxi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
			SUBTOTAL 8. B 1			n/a			n/a
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration datex		Exercise/ Conversion Period xi		Physical or cash settlementxii			Number of voting rights	% of voting rights
					SUBTOTAL 8.B.2			n/a	n/a

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii				X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
Namexv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi

Place of completion	London, UK
Date of completion	2 Oct. 2021

For further information please contact:

Cellular Goods
Alexis Abraham Chief Executive Neil Thapar Investor Relations	+44 207 031 6871 +44 787 645 5323
Tennyson Securities
Corporate Broker Peter Krens	+44 207 186 9030
Novum Securities
Corporate Broker Colin Rowbury Jon Belliss	+44 207 399 9427
Tancredi Intelligent Communication
Media Relations Helen Humphrey Edward Daly Salamander Davoudi cellulargoods@tancredigroup.com	+44 744 922 6720 +44 786 143 0057 +44 795 754 9906

About Cellular Goods PLC

Cellular Goods is a U.K.-based provider of premium consumer products incorporating lab-made cannabinoids. It was established in August 2018 to develop and market efficacy-led and research-backed cannabinoid products. The initial focus is on three categories: premium CBG skincare, CBD ingestibles, and CBD topical athletic recovery formulas. The first products will launch December 2021 and be available direct to consumers through the Company's website.

www.cellulargoods.co 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLFLFVEISLVIIL